Abstract
Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
Keywords: Pancreatic cancer, transforming growth factor beta, tumor microenvironment, immunosuppression, targeted therapies, trabedersen (AP 12009), small molecule inhibitors of TGF-βRI, tumor tissue, antisense compounds, pancreatic adenocarcinoma carries, epithelial cells, antitumoral immune response, growth factors, unique microenvironment harbors, chronic pancreatitis tissue
Current Pharmaceutical Biotechnology
Title: Transforming Growth Factor Beta in Pancreatic Cancer
Volume: 12 Issue: 12
Author(s): Andreas Hilbig and Helmut Oettle
Affiliation:
Keywords: Pancreatic cancer, transforming growth factor beta, tumor microenvironment, immunosuppression, targeted therapies, trabedersen (AP 12009), small molecule inhibitors of TGF-βRI, tumor tissue, antisense compounds, pancreatic adenocarcinoma carries, epithelial cells, antitumoral immune response, growth factors, unique microenvironment harbors, chronic pancreatitis tissue
Abstract: Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
Export Options
About this article
Cite this article as:
Hilbig Andreas and Oettle Helmut, Transforming Growth Factor Beta in Pancreatic Cancer, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808356
DOI https://dx.doi.org/10.2174/138920111798808356 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Automated Brain Tumor Segmentation from MRI Images using Morphometric Algorithms
Current Signal Transduction Therapy An Artificial Neural Network Model for Predicting the Subcellular Localization of Photosensitisers for Photodynamic Therapy of Solid Tumours
Current Medicinal Chemistry Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Virtual Screening of Acetylcholinesterase Inhibitors Based on Machine Learning Combined with Molecule Docking Methods
Current Bioinformatics New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets